Search

PURPOSE To describe the quality assurance (QA) program and early toxicities in the phase III randomized trial BONBIS (NCT00907868) on the role of a localized radiation boost in ductal carcinoma in situ (DCIS). MATERIALS AND METHODS From November 2008 to July 2014, 2004 patients were randomized in arm A (only whole breast radiotherapy, WBRT) and arm B (WBRT + boost). The QA program involved 44 participant centers that performed the dummy run (DR). Compliance and uniformity of clinical target volume (CTV) delineations, and dose prescription and delivery according to the BONBIS trial radiotherapy guidelines were analyzed. Acute toxicities (during and up to 3 months after radiotherapy completion, NCI-CTCAE v3.0 classification) were evaluated in 1929 patients. RESULTS The differences in whole breast CTV (CTV1) and planning target volume (PTV1) were ≤10%, and the differences in boost CTV (CTV2) and PTV (PTV2) were ≥20% compared with the reference DR values; 95% of the prescribed dose encompassed 98.7% and 100% of the median CTV1 and CTV2. Grade ≥2 breast erythema (38.3% vs. 22.4% of grade 2 and 5.4% vs. 2.1% of grade 3, p

International audience; Background: Rate of abdominoperineal resection (APR) varies from countries and surgeons. Surgical impact of preoperative treatment for ultra-low rectal carcinoma (ULRC) initially indicated for APR is debated. We report the 10-year oncological results from a prospective controlled trial (GRECCAR 1) which evaluate the sphincter saving surgery (SSR).Methods: ULRC indicated for APR were included (n = 207). Randomization was between high-dose radiation (HDR, 45 + 18 Gy) and radiochemotherapy (RCT, 45 Gy + 5FU infusion). Surgical decision was based on tumour volume regression at surgery. SSR technique was standardized as mucosectomy (M) or partial (PISR)/complete (CISR) intersphincteric resection.Results: Overall SSR rate was 85% (72% ISR), postoperative morbidity 27%, with no mortality. There were no significant differences between the HDR and RCT groups: 10-year overall survival (OS10) 70.1% versus 69.4%, respectively, 10.2% local recurrence (9.2%/14.5%) and 27.6% metastases (32.4%/27.7%). OS and disease-free survival were significantly longer for SSR (72.2% and 60.1%, respectively) versus APR (54.7% and 38.3%). No difference in OS10 between surgical approaches (M 78.9%, PISR 75.5%, CISR 65.5%) or tumour location (low 64.8%, ultralow 76.7%).Conclusion: GRECCAR 1 demonstrates the feasibility of safely changing an initial APR indication into an SSR procedure according to the preoperative treatment tumour response. Long-term oncologic follow-up validates this attitude.

We present the updated recommendations of the French society of oncological radiotherapy for rectal cancer radiotherapy. The standard treatment for locally advanced rectal cancer consists in chemoradiotherapy followed by radical surgery with total mesorectal resection and adjuvant chemotherapy according to nodal status. Although this strategy efficiently reduced local recurrences rates below 5% in expert centres, functional sequelae could not be avoided resulting in 20 to 30% morbidity rates. The early introduction of neoadjuvant chemotherapy has proven beneficial in recent trials, in terms of recurrence free and metastasis free survivals. Complete pathological responses were obtained in 15% of tumours treated by chemoradiation, even reaching up to 30% of tumours when neoadjuvant chemotherapy is associated to chemoradiotherapy. These good results question the relevance of systematic radical surgery in good responders. Personalized therapeutic strategies are now possible by improved imaging modalities with circumferential margin assessed by magnetic resonance imaging, by intensity modulated radiotherapy and by refining surgical techniques, and contribute to morbidity reduction. Keeping the same objectives, ongoing trials are now evaluating therapeutic de-escalation strategies, in particular rectal preservation for good responders after neoadjuvant treatment, or radiotherapy omission in selected cases (Greccar 12, Opera, Norad).

Adjuvant radiotherapy is one of the major anticancer treatments in early breast cancer patients. Acute and late radio-induced effects may occur during or after breast cancer radiotherapy, and their medical management is a major issue for radiation oncologists. Here, the present review of literature embraces complementary non-pharmacological interventions, which could be combined to adjuvant radiotherapy in order to improve patients care.

Oncosexuality has recently become a new supportive care mission. Sexual morbidity is, routinely, underestimated and must be questioned. We report here the most frequent disorders for men and for women, how to prevent them and how to treat them.

Tailored neoadjuvant treatment of locally advanced rectal cancer (LARC) may improve outcomes. The aim of this study was to determine early MRI prognostic parameters with which to stratify neoadjuvant treatment in patients with LARC.All patients from a prospective, phase II, multicentre randomized study (GRECCAR4; NCT01333709) were included, and underwent rectal MRI before treatment, 4 weeks after induction chemotherapy and after completion of chemoradiotherapy (CRT). Tumour volumetry, MRI tumour regression grade (mrTRG), T and N categories, circumferential resection margin (CRM) status and extramural vascular invasion identified by MRI (mrEMVI) were evaluated.A total of 133 randomized patients were analysed. Median follow-up was 41·4 (95 per cent c.i. 36·6 to 45·2) months. Thirty-one patients (23·3 per cent) developed tumour recurrence. In univariable analysis, mrEMVI at baseline was the only prognostic factor associated with poorer outcome (P = 0·015). After induction chemotherapy, a larger tumour volume on MRI (P = 0·019), tumour volume regression of 60 per cent or less (P = 0·002), involvement of the CRM (P = 0·037), mrEMVI (P = 0·026) and a poor mrTRG (P = 0·023) were associated with poor outcome. After completion of CRT, the absence of complete response on MRI (P = 0·004), mrEMVI (P = 0·038) and a poor mrTRG (P = 0·005) were associated with shorter disease-free survival. A final multivariable model including all significant variables (baseline, after induction, after CRT) revealed that Eastern Cooperative Oncology Group performance status (P = 0·011), sphincter involvement (P = 0·009), mrEMVI at baseline (P = 0·002) and early tumour volume regression of 60 per cent or less after induction (P = 0·007) were associated with relapse.Baseline and early post-treatment MRI parameters are associated with prognosis in LARC. Future preoperative treatment should stratify treatment according to baseline mrEMVI status and early tumour volume regression.El tratamiento neoadyuvante personalizado del cáncer de recto localmente avanzado (locally advanced rectal cancer, LARC) puede mejorar los resultados. El objetivo de este estudio fue determinar factores pronósticos precoces mediante RMN para estratificar el tratamiento neoadyuvante en pacientes con LARC. MÉTODOS: Todos los pacientes de un eensayo prospectivo de fase II, multicéntrico y aleatorizado (GRECCAR4-NCT01333709) se incluyeron en este estudio y se les realizó una RMN antes del tratamiento, 4 semanas después de la quimioterapia de inducción y después de completar la quimiorradioterapia (chemoradiation, CRT). Se evaluó la volumetría tumoral, el grado de regresión tumoral mediante RMN (MRI Tumor Regression Grade, mrTRG), la estadificación T, la estadificación N, el estado del margen de resección circunferencial (circumferential resection margin, CRM) y la presencia de invasión extramural vascular en la RMN (extramural vascular invasion, mrEMVI).Se analizaron 133 pacientes aleatorizados. La mediana de seguimiento fue de 41,4 meses (i.c. del 95%: 36,6-45,2). En 31 pacientes (23%) se diagnosticó una recidiva. En el análisis univariado de la situación basal, mrEMVI fue el único factor pronóstico asociado con un peor resultado (P = 0,0152). Después de la quimioterapia de inducción, un volumen tumoral más alto en la RMN (P = 0,019), una regresión del volumen tumoral ≤ 60% (P = 0,002), la afectación del CRM (P = 0,037), mrEMVI (P = 0,026) y un grado escaso mrTRG (P = 0,023) se asociaron con un mal resultado. Después de completar la CRT, la ausencia de respuesta completa en la RMN (P = 0,004), la presencia de mrEMVI (P = 0,04) y una insuficiente mrTRG (P = 0,005) se asociaron con una supervivencia libre de enfermedad más corta. En el modelo multivariable final en el que se incluyeron todas las variables significativas (basales, postinducción, post-CRT), el estado de ECOG (P = 0,011), la afectación esfinteriana (P = 0,009), la presencia de EMVI al inicio (P = 0,002) y una regresión precoz del volumen tumoral ≤ 60% después de la inducción (P = 0,007) se asociaron con una recidiva. CONCLUSIÓN: Los parámetros basales y post-tratamiento precoces de la RMN se asocian con el pronóstico en el LARC. La estrategia terapéutica preoperatoria futura deberá estratificar el tratamiento de acuerdo con la presencia de EMVI al inicio y la regresión precoz del volumen tumoral.

Background and Purpose: Recent phase 3 clinical trials have evaluated the addition of bevacizumab (B) to standard chemotherapy in the treatment of patients with non-metastatic breast cancer. But few data are available about the tolerance of B with locoregional radiation therapy (RT). The objective was to evaluate the 5 years late toxicities of the concurrent B and RT in non-metastatic breast cancer. Material and methods: This is a multicenter prospective study including non-metastatic breast cancer patients enrolled in phase 3 clinical trials evaluating B with concurrent RT (BEATRICE, BETH, BEVERLY 1, BERVERLY 2) versus RT alone. All patients received neo-adjuvant or adjuvant chemotherapy and normo-fractionated breast or chest wall RT, with or without regional lymph nodes RT. B was administrated as an equivalent of 5 mg/kg every week for 1 year. The safety profile (using the Common Terminology Criteria for Adverse Events version 3.0) was evaluated at 1, 3 and 5 years after the completion of radiotherapy. Results: From October 2007 to January 2012, 151 patients totally included. Median follow-up was 60 months (36-84) and 5 years late toxicities were available for 104 patients (46 with B and RT, 58 with RT alone). Median age was 51 (22-81). 61% of patients received regional lymph nodes RT. The majority of tumor was triple negative (65.6%), tumor size Conclusion: Concurrent B and locoregional RT provides acceptable 5-years toxicities in patients with non-metastatic breast cancer. No grade ≥3 toxicity was observed. Citation Format: Clément-Zhao A, Tanguy M-L, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-06.

Introduction et but de l’etude Comparer les objectifs cliniques et la tolerance de la (chimio)radiotherapie chez des patients avec un carcinome epidermoide du canal anal selon l’infection par le virus de l’immunodeficience humaine (VIH). Materiel et methodes Il s’agissait d’une analyse en sous-groupe de la cohorte multicentrique, prospective et retrospective, Anabase, menee par la Federation francaise de cancerologie digestive (FFCD). Les objectifs cliniques incluaient la survie globale, la survie specifique, la survie sans recidive, le controle locoregional, la survie sans colostomie, le taux de reponse a 4–6 mois et la toxicite aigue et tardive severe (de grade 3 ou plus). Les facteurs pronostiques des principaux objectifs cliniques ont ete recherches. Resultats et analyse statistique Entre fevrier 2016 et avril 2020, 1097 patients atteints d’un carcinome epidermoide localise traite par irradiation ont ete inclus dans Anabase. Seuls les 488 patients avec un statut VIH connu ont ete inclus dans cette analyse (86 patients positifs et 402 patients negatifs issus de 50 centres). Le suivi median etait de 35,8 mois. Les caracteristiques tumorales initiales etaient comparables dans les deux groupes (stades T, X2 = 0,32 et N, X2 = 0,54). Les patients VIH-positifs etaient plus jeunes (p Tableau 1 et montrent que les taux de survie globale, controle locoregional et de survie sans colostomie etaient significativement diminues chez les patients infectes par le VIH. Il n’existait pas de difference significative pour la reponse a 4-6 mois, les taux de survie sans recidive et de survie specifique. La tolerance du traitement etait similaire dans les deux groupes (47,7 % de toxicite aigue de grade 3 ou plus chez les patients infectes par le VIH contre 45 % chez les patients non infectes, p = 0,65). Le sexe masculin, le statut OMS ≥ 1 et l’absence de reponse complete a 4–6 mois etaient associes a une survie globale diminuee en analyse uni- et multivariee. Conclusion Les patients infectes par le VIH recevant une (chimio)radiotherapie pour un carcinome epidermoide du canal anal avaient des taux de survie globale et sans colostomie inferieure a ceux des patients non infectes, ainsi qu’un controle locoregional moindre. La toxicite de ce traitement avec les techniques modernes d’irradiation conformationnelle avec modulation d’intensite n’etait pas majoree chez ces patients.

This phase III trial included patients with ultra-low rectal adenocarcinoma that initially required abdominoperineal resection. The surgical decision was based on clinical tumour status after preoperative treatment. The overall sphincter-saving resection rate was 85 per cent, with 72 per cent rate of intersphincteric resection. Long-term results showed that changing the initial abdominoperineal resection indication into a sphincter-saving resection according to tumoral response is oncologically safe. Saving the sphincter

To evaluate our long-term experience on one-day breast intraoperative radiotherapy (IORT) given as sole radiation treatment to selected patients with breast cancer.Inclusion criteria of INTRAOBS study (prospective observational study) were: ER+ T1N0 unifocal ductal carcinoma; absence of lymphovascular invasion or of extensive intraductal component (Scarff-Bloom-Richardson grade III and HER2+++ excluded). Two different linacs were used (20Gy/1 fraction): one dedicated electron linac (October 2011), and afterwards a mobile linac (50kV photons). The primary endpoint was the local recurrence rate (=ipsilateral breast cancer recurrences number). Secondary endpoints were recurrence-free survival (RFS), overall and specific survival, cosmetic results, and patient satisfaction.Of the present pre-planned analysis for the first 200 patients (median age: 68 years; range, 59-87 years) who received IORT between January 2010 and October 2014 (median follow-up of 53.4 months). A total of 193 patients were still alive. The local recurrence rate was 2.5% (n=5). The 1- and 5-year local RFS rates were 100% and 95.2%, respectively. At 12 months post-surgery, satisfaction about IORT was excellent for 86.9% of patients. Cosmetic results were considered by patients and physicians as good or very good in 89.4% and 97.3% of cases, respectively.IORT for selected patients with breast cancer shows low recurrence rates, good cosmetic outcomes and excellent satisfaction.

Purpose To determine the 3 years late toxicity among patients with non-metastatic breast cancer who received concurrent bevacizumab and locoregional radiotherapy. Material and methods This is a single-arm, multicentre, prospective study, of the toxicity of adjuvant concomitant association of bevacizumab and radiotherapy in patients with breast cancer. Toxicity was assessed by the Common Terminology Criteria for Adverse Events version 3.0 during the radiotherapy and follow-up clinics at 12 and 36 months after its completion. The study was designed to evaluate the toxicity at one year, 3 years and 5 years. Results Sixty-four patients were included from October 2007 to August 2010. All of them received concurrent adjuvant radiotherapy and bevacizumab (in 24 cases after primary systemic treatment). All patients received non-fractionated radiotherapy to breast or chest wall with or without irradiation of regional lymph nodes. Early toxicity has been previously reported. Median follow-up was 46.4 months (range: 18–77 months). Median age was 53 years old (range: 23–68 years). The 3-years overall survival was 93% (range: 87–100%). Evaluation of the toxicity at 3 years was available for 67% of the patients. There was a low rate of toxicity: 14% grade 1 pain, 9% grade 1 fibrosis, 2% grade 1 telangiectasia, 2% grade 1 paresis, 7% grade 1 lymphedema and 2% grade 3 lymphedema. No grade 4 toxicity was observed. No patient had a left ventricular ejection fraction below 50% at 3 years. Conclusions Concurrent bevacizumab with locoregional radiotherapy is associated with acceptable 3-years toxicity in patients with breast cancer.

Purpose/Objectives The purpose of this study was to determine early and late toxicities among patients with non-metastatic breast cancer (BC) receiving concurrent bevacizumab (BV) and radiation therapy (RT). Materials/Methods Multicentre, prospective study, of the toxicity of adjuvant concomitant association of BV and RT in patients with non-metastatic BC enrolled in Phase 3 BEATRICE, BEVERLY and BETH trial. Early and late toxicities were assessed by the Common Terminology Criteria for Adverse Events v. 3.0 during RT, 12 months and 36 months after its completion. Results Sixty-four patients were included from october 2007 to august 2010. They all received adjuvant RT and BV concomitant treatment, plus neo-adjuvant BV for 24 patients. RT was adjuvant and normo-fractionated. Twelve months toxicity was available for 60 patients and 36 months toxicity was available for 43 patients. Median follow-up was 46 months (18-77). Median age was 51 years old (23-68). Among 63 evaluated patients during RT, acute radiation dermatitis was observed in 48 (76%) patients : Grade 1 for 27 (43%), grade 2 for 17 (27%), grade 3 for 4 patients (6%). Grade 2 acute oesophagitis was observed in 1 patient. At 3 years, few toxicities were observed : 6 patients (14%) had grade 1 pain, 4 (9%) had grade 1 fibrosis, one (2%) had grade 1 telangiectasis, one (2%) had grade 1 paresis, 3 (7%) had grade 1 lymphoedema and one grade 3 lymphoedema. No grade 4 toxicity was observed. At 12 months, only one evaluated patient had a LVEF Conclusions Concurrent bevacizumab with locoregional RT is associated with acceptable early and late 3-years toxicities in patients with BC. Determination of late toxicity at 60 months is currently underway. Citation Format: Dautruche A, Belin L, Cottu P, Bontemps P, Lemanski C, De La Lande B, Baumann P, Missohou F, Levy C, Peignaux K, Reynaud-Bougnoux A, Denis F, Gobillion A, Ady Vago N, Fourquet A, Kirova Y. Radiotherapy associated with concurrent bevacizumab in patients with non-metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-10-17.

Standard of care in breast cancer management is well-defined. However, some gray zones still exist, in particular adjuvant radiotherapy indications in case of pN1mi breast cancer. Here we propose to define their prognosis, to underpin the benefit of adjuvant treatments in such patients' management and to define lymphedema risk, which is the most common late side effect of locoregional treatments.

Randomized trials demonstrated similar overall survival between mastectomy and breast-conservative surgery followed by adjuvant radiation therapy. Breast-conservative surgery, with adjuvant radiation therapy, with or without neoadjuvant systemic therapy has become the standard of care for women with early or locally advanced breast cancer. Nevertheless, certain cardiac, lung or cutaneous toxicities may alter the long-term body image and the quality of life of a limited number of patients who consider having had "overtreatment" or treatment outside the best knowledge of science. In case of low-risk breast cancer, several trials have evaluated the carcinologic outcome in absence of radiation therapy after breast-conservative surgery. Local recurrences increased in case of breast-conservative surgery alone but without impact on overall survival. Multiple debates have emerged in order to select the most appropriate evaluation criteria. Finally, a large consensus has considered that reducing local recurrences is important but with modern technologies and after identifying patients of individual radiosensitivity. Indeed, in case of a low absolute risk of local recurrence, radiation therapy techniques have been developed to allow a focal treatment especially for patients with high risk of developing late effects. This kind of compromise takes into account the reduction risk of local recurrences but also the probability of developing radiation-induced cutaneous sequelae. In the same way, for patients considered at high risk of recurrence, the huge volumes need specific techniques to better cover the targets while protecting the surrounding critic organs such as heart and lung. Intensity-modulated radiation therapy and the local high boost may help to decrease local recurrences of these more extended and aggressive diseases while considering the individual radiosensitivity that paves the way of long-term sequelae. In this article, we detail a personalized approach of breast radiation therapy considering the absolute risk of local recurrences and the probability of radiation-induced toxicity appearance.

We propose in this short review to report the impact of stereotactic body radiation therapy (SBRT) in oligometastatic or oligoprogressive cancer patients in terms of metastatic progression-free and global survival, and to identify the place of SBRT in patient's pathway.

Randomized trials demonstrated similar overall survival between mastectomy and breast-conservative surgery followed by adjuvant radiation therapy. Breast-conservative surgery, with adjuvant radiation therapy, with or without neoadjuvant systemic therapy has become the standard of care for women with early or locally advanced breast cancer. Nevertheless, certain cardiac, lung or cutaneous toxicities may alter the long-term body image and the quality of life of a limited number of patients who consider having had "overtreatment" or treatment outside the best knowledge of science. In case of low-risk breast cancer, several trials have evaluated the carcinologic outcome in absence of radiation therapy after breast-conservative surgery. Local recurrences increased in case of breast-conservative surgery alone but without impact on overall survival. Multiple debates have emerged in order to select the most appropriate evaluation criteria. Finally, a large consensus has considered that reducing local recurrences is important but with modern technologies and after identifying patients of individual radiosensitivity. Indeed, in case of a low absolute risk of local recurrence, radiation therapy techniques have been developed to allow a focal treatment especially for patients with high risk of developing late effects. This kind of compromise takes into account the reduction risk of local recurrences but also the probability of developing radiation-induced cutaneous sequelae. In the same way, for patients considered at high risk of recurrence, the huge volumes need specific techniques to better cover the targets while protecting the surrounding critic organs such as heart and lung. Intensity-modulated radiation therapy and the local high boost may help to decrease local recurrences of these more extended and aggressive diseases while considering the individual radiosensitivity that paves the way of long-term sequelae. In this article, we detail a personalized approach of breast radiation therapy considering the absolute risk of local recurrences and the probability of radiation-induced toxicity appearance.

Resume Nous proposons dans cette revue de rapporter l’impact de la radiotherapie stereotaxique chez les patients ayant un cancer oligometastatique ou en oligoprogression en termes de survie sans progression metastatique et globale, et d’identifier quelle est la place de cette modalite de radiotherapie au sein du parcours–patient.

Ambulatory surgery has originally become possible in breast cancer, thanks to an earlier diagnosis of the disease and less aggressive surgery as well as technological innovations in surgery and anesthesia. At the same time, there was an evolution of mentalities encouraging greater patient autonomy. Its development in France is of major political concern. Above its economical impact, the key point is mostly the patient capacity of a better recovery through a more active management. Furthermore, ambulatory surgery is time-efficient, thus fits very well with today’s way of life.

Adjuvant radiotherapy significantly reduces locoregional recurrences in breast cancer at any stage, from in situ stage to locally advanced tumors, and improves specific survival after conservative surgery or mastectomy for tumors. After decades of uniform external irradiation, technical improvements have dramatically changed the quality of treatment and new technologies now allow therapeutic climbing, offering a wider coverage of volumes with lower toxicities. Early stages tumors can also beneficiate from a drastic de-escalation, by reducing volume, dose, or duration of the radiation treatment. These new schemes are more easily accepted and improve quality of life. “One fits all” times are gone and now each woman must have her personalized radiotherapy.

Depuis plusieurs annees, mais tout particulierement depuis la publication du Plan cancer III, l’entite « Parcours » fait partie de tout discours medical, du cancer a d’autres pathologies, englobant a la fois une notion de parcours de soins, faisant intervenir une fluidite souhaitee entre les differents intervenants, notamment dans le lien precieux ville–hopital, et celle d’une trajectoire transversale d’une pathologie, requerant des specialites diverses, dans un ordre pouvant se modifier en fonction des cas. Si l’on reprend les termes exacts du Plan cancer III, le parcours de soins en cancerologie debute des la forte suspicion ou confirmation du diagnostic, ce qui montre bien la necessaire coordination entre univers differents, celui des bien portants qui ne se savent pas malades et celui des malades qui devront se reintegrer dans ce monde des bien portants ensuite. On privilegiera le bon aiguillage des les premieres etapes, sans errements diagnostiques, necessitant un reseau efficace et de qualite. La prise en charge de la personne potentiellement malade et de l’angoisse generee par cette hypothese est determinante et doit etre priorisee. Si les delais sont mentionnes comme tres importants, l’accent est bien mis sur la pertinence de l’accompagnement dans les etapes initiales qui vont permettre de bâtir un Plan personnalise de soins (PPS), dont les differentes etapes devront s’enchainer sans perte de temps inutile ni errements therapeutiques. L’objectif 7 du Plan cancer insiste tout particulierement sur la prise en charge personnalisee en cancerologie, non pas tant des caracteristiques de la tumeur que celles, biographiques du patient, prenant en compte l’ensemble des besoins de la personne et de ses proches. Ce cheminement commun transversal et global necessite une organisation coordonnee d’interventions pluridisciplinaires afin d’en ameliorer la fluidite et se heurte a l’organisation verticale des institutions, par services (chirurgie, oncologie, radiotherapie...) cloisonnant a la fois les personnes et la diffusion de l’information. Les programmes personnalises de soins, les supports d’information, les traces des propositions therapeutiques devront etre remis et explicites aux patients, afin de leur servir de fil d’Ariane dans ce cheminement (Plan cancer III, page 61). Deja presentes dans le Plan cancer II, ces notions rendent compte de la necessite de responsables de parcours, veillant sur les differents aiguillages de ce chemin de vie particulier, attentifs aux points potentiels de rupture, favorisant une relation constante et simple entre la medecine habituelle du patient et l’univers de l’hopital, amene de surcroit a raccourcir les temps hospitaliers. C’est en raison a la fois de la pertinence de cette notion et de sa difficulte de mise en œuvre que nous avons souhaite toutes trois, a travers nos specialites differentes, mais avec une vue d’ensemble convergente, dedier un numero d’Oncologie a ce theme, mettant en exergue la necessite conditionnelle d’optimisation de travailler ensemble, le patient etant au centre du systeme et devant pouvoir se tourner dans chaque direction, accompagne d’un meme discours dans un vecu d’empathie et d’entraide. Avec cynisme, mais beaucoup de realisme, Alain Demaille, directeur du centre de lutte contre le cancer de Lille, stigmatisait deja en 1991 la difficulte de l’exercice, necessitant partage, transversalite et humilite [1]

IF 4.942 (2017); International audience

Introduction et but de l’etude Le second traitement conservateur emerge comme une option therapeutique en cas de second evenement tumoral du sein homolateral apres chirurgie conservatrice et irradiation du sein. Nous rapportons les resultats d’une comparaison entre second traitement conservateur et mastectomie de rattrapage en cas de second evenement tumoral du sein homolateral. Materiel et methodes Les resultats oncologiques apres le traitement d’un second evenement tumoral du sein homolateral ont ete analyses par etude appariee (score de propension) pour des patients atteints d’un second evenement tumoral du sein homolateral diagnostique entre 01/2000 et 12/2014. Le second traitement conservateur etait soit une tumorectomie et une curietherapie, soit une mastectomie. L’appariement (1 :1) a ete realise par la methode du “nearest neighbor” (incluant les donnees relatives au second evenement tumoral du sein homolateral : âge, intervalle entre le premier et le second evenement tumoral du sein homolateral, taille tumorale, type et grade histologique, expression des recepteurs hormonaux et Her2, chimiotherapie, hormonotherapie et periode du second evenement tumoral du sein homolateral). L’objectif primaire etait la survie sans maladie. Les objectifs secondaires etaient la survie globale, la survie sans metastase et la survie sans troisieme evenement tumoral du sein homolateral. Resultats et analyse statistique Parmi les 1329 patientes dont les dossiers ont ete analyses (mastectectomie : 942 ; second evenement tumoral du sein homolateral : 387), 430 ont ete appariees par score de propension (mastectectomie : 215/2 ; second traitement conservateur : 215). Le suivi median etait de 65 mois pour la mastectectomie (intervalle de confiance a 95 % [IC 95 %] : [58-78]) et de 68 mois (IC 95 % : [57-75]) pour le second traitement conservateur (p = 0,28). En analyse appariee, il n’y avait aucune difference a 5 ans pour la survie sans maladie entre la mastectomie et le second traitement conservateur (78 % ; IC 95 % : [71-84]) contre (82 % ; IC 95 % : [76–89] ; p = 0,22). Aucune difference a 5 ans n’a ete observee pour la survie globale (90 %, IC 95 % : [86–95]) contre 86 %, (IC95 % : [81–92] ; p = 0,85), la survie sans metastase (92 %, IC 95 % : [87–96]) contre 94 %, (IC 95 % : [90–98] ; p = 0,75) et la survie sans troisieme evenement tumoral du sein homolateral (94 %, IC 95 % : [90–98]) contre 98 %, (IC 95 % : [95–1] ; p = 0,17). Conclusion Il s’agit de l’analyse appariee la plus importante entre la mastectomie et le second traitement conservateur en cas de second evenement tumoral du sein homolateral. Compare a la mastectomie, le second traitement conservateur (tumorectomie avec curietherapie) ne semble pas etre associe a une difference significative en termes de survie sans maladie, survie globale, survie sans metastase et survie sans troisieme evenement tumoral du sein homolateral. Le second traitement conservateur peut donc etre considere comme une option de traitement de rattrapage.

Les dernieres RPC sur le traitement neoadjuvant du cancer du rectum dataient de 2005. Elles ont ete mises a jour en integrant les dernieres publications. Pour les tumeurs T3 ou T4, une IRM est recommandee pour preciser la marge circonferentielle. Aucun des examens d’imagerie ne peut predire avec precision le statut ganglionnaire. La RT preoperatoire diminue le taux de recidive locale mais altere le resultat fonctionnel digestif et la fonction sexuelle apres chirurgie conservatrice. Les cancers du haut rectum resecables d’emblee ne doivent pas beneficier d’un traitement neoadjuvant. Pour les tumeurs du tiers moyen et du tiers inferieur du rectum, l’indication depend de l’evaluation en imagerie. Certaines tumeurs avec une bonne marge circonferentielle peuvent etre traitees par chirurgie d’emblee. Les tumeurs mrT3d et T4 doivent beneficier d’une radiochimiotherapie. La CT associee a la RT repose sur le 5FU oral (capecitabine). L’utilisation du FU IV est une alternative possible. Il n’y a pas d’interet a ajouter une autre molecule de chimiotherapie. Apres RT courte, la chirurgie doit etre realisee au maximum 7 jours suivants l’irradiation. Apres CTRT, il ne semble pas necessaire de prolonger le delai d’attente au dela de 6-8 semaines.

In addition to achieve breast conserving surgery after neoadjuvant chemotherapy, its indications are growing, especially in Her2 overexpressing and triple negative breast cancers owing to the emergence of new targeted therapies. Radiotherapy belongs to breast cancer management. However, some questions are still unresolved regarding nodes area irradiation after neoadjuvant chemotherapy. This short communication reviews indications of radiotherapy of node areas in breast cancer after neoadjuvant chemotherapy.

Irradiation of node areas is still a complex challenge in external radiotherapy for breast cancer. Acceptable target coverage is always balanced by protection of organs at risk and patient morphology. Intensity-modulated radiotherapy increases the quality of dose distribution on the planning target volume, but modifies dramatically the irradiation coverage of critical structures in a different way compared to 3D treatment. In this paper we analyze this new technique in breast treatment with node regions, its expected gain and potential risks.

Hydraulic fracturing has been applied to exploit hydrocarbon resources for a number of decades. During the fracturing process, large amounts of pressurized fracturing fluid is injected to create and to propagate the fracture. In the exploitation of unconventional reservoirs, fracturing fluid recovery can be very low and even less than 10%. Any unrecovered fracturing fluid can be imbibed into the formation and block the rock pores, thus reducing the effective permeability of gas and causing gas production impairment. This study investigates gas production impairment due to spontaneous migration of fracturing fluid into a shale formation as a function of shut-in time. Core flooding experiments were designed to mimic initial leak-off volume, followed by shut-in time and flow back. Results are presented in terms of regained permeability ratios as a function of shut-in time. Findings from this work indicate that the regained permeability of shale slightly decreases with shut-in time, as the fluid front propagates within the rock. Results are also compared to previous experiments on tight sand cores. From this comparison, it was concluded that lithology also plays a determining factor in the relationship between shut-in time and regained permeability. The level of impairment caused by fracturing fluid migration was found to be significantly higher in shale cores than tight sands, which is attributed to the inherent lower permeability of shale formations.

International audience; Aim: Women of reproductive age with breast cancer generally receive gonadotoxic chemotherapy. Fertility issues are of great concern for them. However, little is known on ovarian damage during chemotherapy and its evolution during long-term follow-up. The Anti-Mü llerian hormone; Ovarian reserve; Amenorrhea aim of this study was to provide a detailed description of serum anti-Mü llerian hormone (AMH) evolution during chemotherapy and 24-month follow-up.Methods: This prospective cohort study was conducted in 250 patients, aged 18e39 years, diagnosed with breast cancer and treated with adjuvant/neoadjuvant chemotherapy. Each patient underwent blood AMH measurement at each chemotherapy cycle, and at 6, 12 and 24 months after chemotherapy. Menses occurrence was also recorded.Results: Mean basal AMH level was 4.19 AE 4.84 ng/mL, and was negatively correlated with age. Serum AMH level rapidly decreased in all patients after each chemotherapy cycle to undetectable levels in most of them, and slowly increased in 45% of the patients during the 24-month follow-up. AMH decrease was significantly associated with age and basal AMH level, but not with cyclophosphamide dose and tamoxifen use. The prevalence of chemotherapy-related amenorrhoea was 92.4% at the end of chemotherapy; women with amenorrhoea being significantly older and having lower basal AMH than women who resumed menses.Conclusions: Our study confirms rapid and deep ovarian reserve alteration in young women receiving chemotherapy for breast cancer, and shows moderate AMH recovery in some patients. Although AMH cannot alone predict fertility potential, these new data emphasise the need for post-treatment ovarian insufficiency follow-up, strongly support the use of fertility preservation strategies and may provide new tools for improved counselling.

IF 4.328; International audience

International audience; Irradiation techniques for breast cancer (arctherapy, tomotherapy) are evolving and intensity-modulated radiation therapy is being increasingly considered for the management of these tumours. Here, we propose a review of intensity-modulated radiation therapy planning issues, clinical toxicities and indications for breast cancer.

Irradiation techniques for breast cancer (arctherapy, tomotherapy) are evolving and intensity-modulated radiation therapy is being increasingly considered for the management of these tumours. Here, we propose a review of intensity-modulated radiation therapy planning issues, clinical toxicities and indications for breast cancer.

Objectif de l’etude Il s’agissait de demontrer la faisabilite d’utilisation de marges de volume cible previsionnel reduites a 5 mm lors d’une radiotherapie conformationnelle avec modulation d’intensite (RCMI) et guidee par l’image de cancers de l’œsophage. Materiel et methode Nous avons inclus dans cette etude les patients pris en charge en 2016 par RCMI pour un cancer primitif de l’œsophage cervical ou thoracique, de tout stade TNM et de tout type histologique. Des marges de volume cible previsionnel reduites a 5 mm dans toutes les directions ont ete etudiees retrospectivement. Le guidage par l’image a ete realise quotidiennement, soit par deux images orthogonales de basse energie (kV-kV), soit par tomographie conique (CBCT). Le recalage a ete realise par un manipulateur d’electroradiologie medicale. L’ensemble des recalages realises a l’aide des tomographies coniques ont ete regardes a posteriori par un medecin afin de verifier la couverture tumorale par ce volume cible previsionnel reduit, et les differences de recalage ont ete relevees entre manipulateur et medecin dans les trois plans de l’espace. Resultats Trente patients ont ete inclus. Il y avait 18 carcinomes epidermoides (60 %), huit adenocarcinomes (27 %) et trois carcinomes neuroendocrines (10 %). La localisation etait l’œsophage thoracique dans 93 % des cas (10 % le tiers superieur, 33 % le tiers moyen, 30 % le tiers inferieur, 20 % les tiers moyen et inferieur), et cervical dans 7 % des cas. Apres tomographie conique, 145 recalages ont ete verifies (deux a cinq par patient, au maximum un par semaine). La couverture tumorale par le volume cible previsionnel etait assuree dans 61 % des cas avant la tomographie conique et dans 95 % des cas apres. La couverture tumorale n’etait pas satisfaisante dans sept tomographies coniques, pour cinq patients differents. Les differences de recalage entre manipulateur et medecin dans les trois plans de l’espace etaient inferieures a 5 mm dans 96 % des cas. Le maximum de difference de recalage a ete retrouve pour le tiers inferieur de l’œsophage thoracique. Conclusion Une marge de volume cible previsionnel de 5 mm semble suffisante pour la RCMI des cancers de l’œsophage en cas de guidage par l’image par tomographie conique. Un suivi carcinologique a long terme est necessaire.

Objectif de l’etude Evaluation des pratiques, traitements et resultats des cancers du canal anal dans la cohorte nationale Anabase. Materiel et methode Cette cohorte observationnelle multicentrique a inclus tous les patients pris en charge pour un carcinome du canal anal dans 62 centres francais depuis janvier 2015. Nous presentons les caracteristiques des patients et des tumeurs, les traitements et les resultats, ainsi que les facteurs associes a la reponse complete a 6 mois en analyse uni- et multifactorielle. Resultats Entre janvier 2015 et fevrier 2018, 448 patients ont ete pris en charge pour un carcinome du canal anal non metastatique par radiotherapie ou chimioradiotherapie : 106 hommes (23,6 %) et 342 femmes (76,4 %), d’âge median 64 ans [35–97]. Les tumeurs etaient limitees (T1-2, N0, M0) pour 197 patients (44 %) et localement evoluees (T3-4 ou N+, M0) pour 251 (56 %). Une chimioradiotherapie a ete delivree a 348 patients (77,7 %), avec une chimiotherapie a base de mitomycine (86 %), de cisplatine (4 %) ou de 5-fluoro-uracile seul (8 %), et une chimiotherapie neoadjuvante a 40 patients (8,8 %). La radiotherapie etait conformationnelle avec modulation d’intensite (RCMI ; 83 %) ou conformationnelle tridimensionnelle (17 %) avec une dose totale mediane de 60 Gy [extremes : 14–71 Gy] et une interruption pour 170 patients (planifiee : 59 %). Six mois apres radiotherapie, parmi 350 patients, 72 % etaient en situation de reponse complete, 18 % de reponse partielle ou de stabilisation et 10 % de progression. Les facteurs associes a la reponse complete a 6 mois en analyse unifactorielle etaient le stade initial limite (Odds ratio [OR] = 1,8, intervalle de confiance a 95 % [IC 95 %] = 1,1–3,0, p = 0,013), la taille tumorale de moins de 3 cm (OR = 2,2, 95 %IC = 1,2–3,9, p = 0,009), alors que la chimiotherapie neoadjuvante (OR = 0,4, IC 95 % = 0,2–0,7, p = 0,003) et la dose de radiotherapie ( Conclusion Les premiers resultats de la cohorte Anabase montrent une bonne adequation aux recommandations (RCMI, chimiotherapie a base de mitomycine). Neanmoins, une pause planifiee et une chimiotherapie neoadjuvante sont encore pratiquees dans certains centres.

International audience; BACKGROUND:Accelerated partial breast irradiation (APBI) is an option for adjuvant radiotherapy according to ASTRO and ESTRO recommendations. Among the available techniques, volumetric-modulated arc therapy (VMAT) is attractive but has not been extensively studied for APBI. This study assessed its feasibility, tolerance and early oncological outcomes.METHODS:We analysed the data of nine patients (median age 74 years) with ten lesions (one bilateral cancer) treated from May 2011 to July 2012 with APBI using VMAT. The radiation oncologist delineated the surgical tumour bed, and added an 18 mm isotropic margin to obtain the planning target volume (PTV). The dose was 40 Gy prescribed in 4 Gy fractions given twice a day over five days. Patients were regularly followed for toxicities and oncological outcomes.RESULTS:Mean PTV was 100.0 cm(3) and 95 % of the PTV received a mean dose of 99.7 % of the prescribed dose. Hot spots represented 0.3 % of the PTV. 6.2 %, 1.6 % and 0.3 % of the ipsilateral lung volume received 5 Gy (V5Gy), 10 Gy (V10Gy) and 20 Gy (V20Gy), respectively. Regarding the contralateral lung, V5Gy was 0.3 %, and V10Gy and V20Gy were nil. V5Gy accounted for 3.1 % of the heart. An average 580 monitor units were delivered. No acute or late grade ≥ 2 toxicities were observed. With a median follow-up of 26 months, no relapses occurred.CONCLUSION:In our study, VMAT allowed optimal dosimetry with consequential high therapeutic ratio in elderly and frail patients.

International audience; Irradiation of node areas is still a complex challenge in external radiotherapy for breast cancer. Acceptable target coverage is always balanced by protection of organs at risk and patient morphology. Intensity-modulated radiotherapy increases the quality of dose distribution on the planning target volume, but modifies dramatically the irradiation coverage of critical structures in a different way compared to 3D treatment. In this paper we analyze this new technique in breast treatment with node regions, its expected gain and potential risks.; L’irradiation des aires ganglionnaires de drainage du sein reste complexe dans le cadre d’une classique radiothérapie conformationnelle tridimensionnelle. La bonne couverture des volumes cibles est souvent compromise par la morphologie de la patiente et la protection des organes à risque. La radiothérapie conformationelle avec modulation d’intensité permet d’améliorer cette couverture mais modifie la distribution de la dose délivrée aux organes à risque par rapport à celle connue avec les techniques passées. Nous rapportons ici l’analyse de cette nouvelle technique, de son gain probable et de ses risques potentiels.

International audience

Objectif de l’etude Evaluer le devenir a long terme de patients pris en charge pour un carcinome anal par radiotherapie conformationnelle avec modulation d’intensite (RCMI). Materiel et methode Entre aout 2007 et septembre 2015, 233 patients atteints d’un carcinome epidermoide du canal anal ont ete pris en chage par RCMI, notamment par arctherapie volumetrique depuis 2009. L’irradiation delivrait 45 Gy en 25 fractions d’1,8 Gy, cinq jours par semaine, a la tumeur initiale et aux aires ganglionnaires pelviennes et inguinales (premier volume cible previsionnel, PTV1). Un boost (non integre) de 14,4 a 20 Gy etait ensuite administre a la tumeur initiale (deuxieme volume cible previsionnel, PTV2), par fractions de 1,8-2 Gy ou par curietherapie. Les tumeurs localement evoluees recevaient une chimiotherapie concomitante par 5-fluoro-uracile-mitomycine ou 5-fluoro-uracile -cisplatine. La toxicite a ete etudiee avec l’echelle Common Terminology Criteria for Adverse Events, version 4.0. L’etude des 166 premiers patients est presentee ici. Resultats Les dossiers de 124 femmes (75 %) et 42 hommes (25 %) ont ete analyses. L’âge median etait 61 ans (36–92 ans). Les tumeurs etaient de stades I, II, III et IV chez respectivement 13 %, 25 %, 57 % et 4 % des patients. Treize etaient immunodeprimes, dont dix infectes par le virus de l’immunodeficience humaine (6 %), 132 (80 %) ont recu une chimioradiotherapie et 34 (20 %) une radiotherapie seule. Avec un suivi median de 46,7 mois (intervalle de confince a 95 % [IC95 %] : 41,2–51,6, aucune toxicite tardive de grade 4 n’a ete observee. Vingt patients (12 %) ont souffert d’une toxicite de grade 3, diarrhee, rectite, hematurie, radiodermite, incontinence anale et/ou stenose vaginale. Il n’y avait pas de toxicite hematologique tardive significative ( p = 0,23). Trente-six cancers (22 %) ont recidive, 24 locoregionalement (67 %), 12 a distance isolement (33 %). Trente-trois patients (20 %) ont ete colostomises apres la radiotherapie, dont 17 pour recidive locale et 12 pour toxicite radioinduite. Le taux de survie globale a 3 ans etait de 85,5 % (IC95 % : 78,7–90,3), celui sans recidive locoregionale de 86,9 % (IC95 % : 80,3–91,4), celui sans maladie de 74,6 % (IC95 % : 67,0–80,8) et celui sans colostomie de 81,2 % (IC95 % : 74,0–86,6). Conclusion La RCMI devient un traitement standard des cancers du canal anal. Une analyse dosimetrique completera ces resultats.